All In Biotech

Drug Trial Radar · NCT06308198

A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines

A Phase 3, Multicenter, Randomized, Placebo-Controlled Study of AGN-151586 for the Treatment of Moderate to Severe Glabellar Lines

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 161 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

161

Actual

Start

Mar 29, 2024

Primary completion

Feb 26, 2025

Study completion Feb 26, 2025

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. The purpose of this study is to evaluate the safety and efficacy of AGN-151586 compared to placebo in adult participants. AGN-151586 is an investigational product being developed for the treatment of GL. In the first period, participants are randomly assigned to receive AGN-151586 or placebo. Each group receives a different treatment. There is a 1 in 3 chance that participants will be assigned to placebo. In the second period, all participants who meet retreatment criteria will receive open-label AGN-151586. Around 160 participants will be enrolled in the study at approximately 14 sites in China, Taiwan, and Japan. Participants will receive either AGN-151586 or Placebo administered as 5 intramuscular injections to the glabellar complex on Day 1. Eligible participants may then receive AGN-151586 injections on Day 43 and will be followed for up to 6 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care due to multiple study visits. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Glabellar Lines

Interventions

  • AGN-151586Drug

    Intramuscular Injections

  • PlaceboDrug

    Intramuscular Injections

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with a >= 2-Grade Improvement from Baseline on the Facial Wrinkle Scale with Asian (FWS-A) Guide According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum FrownTime frame: Day 7
  2. Percentage of Participants with a >= 2-Grade Improvement from Baseline on the FWS-A Guide According to Participant Assessment of GL Severity at Maximum FrownTime frame: Day 7
  3. Number of Participants with Adverse Events (AEs)Time frame: Up to approximately Day 84

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Beijing Hospital /ID# 256084

    Beijing, Beijing Municipality, China

  • Dermatology Hospital of Southern Medical University /ID# 256172

    Guangzhou, Guangdong, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 255871

    Wuhan, Hubei, China

  • Nanjing Drum Tower Hospital /ID# 255936

    Nanjing, Jiangsu, China

  • Zhongda Hospital Southeast University /ID# 255937

    Nanjing, Jiangsu, China

  • Wuxi People's Hospital /ID# 256029

    Wuxi, Jiangsu, China

  • Xianyang Hospital of Yan'an University /ID# 256774

    Xianyang, Shaanxi, China

  • Huashan Hospital, Fudan University /ID# 255870

    Shanghai, Shanghai Municipality, China

  • Zhejiang Provincial People's Hospital /ID# 256028

    Hangzhou, Zhejiang, China

  • Tokyo Center Clinic /ID# 267380

    Chuo-ku, Tokyo, Japan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 260669

    Kaohsiung City, Taiwan

  • Tri-Service General Hospital /ID# 260673

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.